Moberg Pharma’s partner launches Kerasal Nail in China

STOCKHOLM, May 19th, 2015. Moberg Pharma AB (OMX: MOB) today announced that its
partner, Menarini Asia-Pacific, has initiated the launch of Kerasal Nail® in
China. TV commercials and other advertising started this week in certain parts
of southern China.
Moberg Pharma’s distribution agreement with the Menarini Group – a top 40 global
pharmaceutical company - includes Italy, China and eight countries in Southeast
Asia. In addition to China, launch activities have previously been initiated in
Malaysia, Singapore and Hong Kong. Preparations are ongoing in the other markets
in the region.

"We are very pleased with the progress and that the launch of Kerasal Nail now
has started in China. Kerasal Nail has significant potential in the region.
Assuming successful launches, we expect the region to become an important
contributor to revenues and earnings from 2015 and onwards," said Peter Wolpert,
CEO of Moberg Pharma AB.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 8.30 a.m. (CET) on May 19, 2015.
For additional information contact:
Peter Wolpert, CEO, Phone: +46 (0)70 - 735 7135, E-mail:
peter.wolpert@mobergpharma.se
Anna Ljung, CFO, Phone: +46 (0)70 - 766 60 30, E-mail:
anna.ljung@mobergpharma.se
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
OTC sales operations in the U.S. and a distributor network in more than 40
countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal
Nail®, Balmex®, Jointflex®, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail®
(Emtrix® or Nalox™ in certain ex-U.S. markets) is a leading OTC treatment of
nail disorders in the U.S., Canada and several EU markets and is currently being
launched in Southeast Asia. The company is growing organically as well as
through acquisitions. Internal development programs focuses on innovative drug
delivery of proven compounds and include two phase II assets, MOB-015
(onychomycosis) and BUPI (oral mucositis). Moberg Pharma has offices in
Stockholm and New Jersey and the company’s shares are listed on the Small Cap
list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB). For further
information, please visit: www.mobergpharma.com.